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Yield of HIV-associated tuberculosis during intensiﬁ ed case 
ﬁ nding in resource-limited settings: a systematic review and 
meta-analysis
Katharina Kranzer, Rein M G J Houben, Judith R Glynn, Linda-Gail Bekker, Robin Wood, Stephen D Lawn
Intensiﬁ ed case ﬁ nding is the regular screening for evidence of tuberculosis in people infected with HIV, at high risk 
of HIV, or living in congregate settings. We systematically reviewed studies of intensiﬁ ed case ﬁ nding published 
between January, 1994, and April, 2009. In 78 eligible studies, the number of people with tuberculosis detected during 
intensiﬁ ed case ﬁ nding varied substantially between countries and target groups of patients. Median prevalence of 
newly diagnosed tuberculosis was 0·7% in population-based surveys, 2·2% in contact-tracing studies, 2·3% in mines, 
2·3% in programmes preventing mother-to-child transmission of HIV, 2·5% in prisons, 8·2% in medical and 
antiretroviral treatment clinics, and 8·5% in voluntary counselling and testing services. Metaregression analysis of 
studies that included only people with HIV showed that for each increment in national prevalence of tuberculosis of 
100 cases per 100 000 population, intensiﬁ ed case ﬁ nding identiﬁ ed an additional one case per 100 screened individuals 
(p=0·03). Microbiological sputum examination of all individuals without prior selection by symptom screening 
yielded an additional four cases per 100 individuals screened (p=0·05). Data on the use of serial screening, treatment 
outcomes in actively identiﬁ ed cases of tuberculosis, and cost-eﬀ ectiveness, however, were lacking. Concerted action 
is needed to develop intensiﬁ ed case ﬁ nding as an important method for control of tuberculosis.
Introduction
The sixth Millennium Development Goal target of 
halving the 1990 prevalence of tuberculosis and death 
rates by 2015 will not be achieved if present trends 
continue.1 Any shortfall from this target worldwide will 
be associated with a failure to achieve these targets in 
sub-Saharan Africa where HIV has seriously undermined 
the control of tuberculosis. Worldwide there are more 
than 1·3 million cases of HIV-associated tuberculosis 
each year, resulting in almost half a million deaths; 
sub-Saharan Africa is estimated to account for 79% of 
this disease burden.2 Although the incidence of 
HIV-associated tuberculosis worldwide is estimated to 
have peaked in 2006,2 more progress is needed in 
reducing prevalence and mortality.
The WHO directly observed short-course strategy, 
which relies on a process of passive tuberculosis case 
ﬁ nding, has helped to control tuberculosis in many parts 
of the world but not in countries with generalised 
epidemics of HIV (prevalence of HIV greater than 1% in 
the general population).2,3 In recognition of this failure, 
WHO and the Stop TB Partnership developed an interim 
policy on collaborative tuberculosis and HIV activities4 
that included additional interventions to reduce the 
burden of tuberculosis in people living with HIV. Within 
this policy the four core prevention strategies for 
tuberculosis were intensiﬁ ed case ﬁ nding, isoniazid 
preventive therapy, tuberculosis infection control, and 
scale-up of antiretroviral therapy.5,6
Despite clear policy guidelines, antiretroviral therapy is 
the only one of the four core strategies that has been used 
at a large scale.6 Use of isoniazid preventive therapy is 
still limited and provided for only 0·1% of individuals 
infected with HIV.2 Data on the use of tuberculosis 
infection control are scarce. Intensiﬁ ed case ﬁ nding 
among patients attending HIV care services reached just 
2·2% of the 33 million people estimated to be living with 
HIV in 2007.2 To address the substantial gap in the 
scale-up of these interventions, WHO launched the 3Is 
policy initiative in 2008, which is a three-pronged strategy 
of intensiﬁ ed case ﬁ nding, isoniazid preventive therapy, 
and tuberculosis infection control to be used with the 
scale-up of antiretroviral therapy.7
Several terms have been used for the screening of 
patients for active tuberculosis. The terms intensive case 
ﬁ nding, active case ﬁ nding, and enhanced case ﬁ nding 
are often used interchangeably and all refer to strategies 
to identify and treat people with tuberculosis who have 
not sought diagnostic services on their own initiative. 
However, whereas intensiﬁ ed case ﬁ nding and active 
case ﬁ nding require face-to-face contact and on-site 
screening, enhanced case ﬁ nding works primarily 
through making populations aware of the symptoms of 
tuberculosis and encouraging self-presentation to 
medical services.8 In the 3Is policy, intensiﬁ ed case 
ﬁ nding is deﬁ ned as “the regular screening of all people 
with HIV or at high risk of HIV or in congregate settings 
(such as mines, prisons, military barracks) for symptoms 
and signs of TB followed promptly with diagnosis and 
treatment”, and this is the deﬁ nition we have used in this 
Review.7 The policy also recommends screening of 
household contacts of people with tuberculosis.7 
Intensiﬁ ed case ﬁ nding is the central intervention of 
the 3Is strategy, because its aim is to identify patients as 
either having active tuberculosis (and in need of 
treatment) or free of the disease (and warranting 
preventive therapy), although in practice the status of 
some patients will be unclear and these patients need 
prospective evaluation. Intensiﬁ ed case ﬁ nding is also 
the key means by which the prevalence of untreated 
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disease can be reduced within clinical services, congregate 
settings, and in the community, thereby reducing the 
transmission of tuberculosis. In view of this new policy 
initiative, there is a great need for data that inform 
development of strategies of intensiﬁ ed case ﬁ nding.
Whereas the speciﬁ c investigations (eg, sputum 
microscopy, sputum culture, chest radiography) used in 
screening for tuberculosis might have an important 
aﬀ ect on the yield of new cases of tuberculosis identiﬁ ed,9 
overall investigational strategy and target group are also 
very important. For example, establishing that a patient 
has the symptoms of tuberculosis has traditionally been 
central to screening strategies, and yet recent studies9–13 
have shown that a proportion of patients with 
HIV-associated tuberculosis have asymptomatic disease 
or very minor symptoms. As a result, the yield of 
intensiﬁ ed case ﬁ nding in some groups might be higher 
if all individuals are investigated without preselection. 
The identiﬁ cation of groups for which intensiﬁ ed case 
ﬁ nding should be prioritised is a further issue. The yield 
of cases of tuberculosis is likely to be highly variable, 
depending on a range of factors that include the local 
prevalence of tuberculosis, the function of local 
tuberculosis control services, the prevalence of HIV in 
the target group, and the degree of associated 
immunodeﬁ ciency. In turn, the prevalence of tuberculosis 
detected established the number needed to screen (NNS) 
to identify one new case of undiagnosed active 
tuberculosis. Other important factors aﬀ ecting decisions 
on implementing intensiﬁ ed case ﬁ nding include the 
feasibility and cost of the screening, the laboratory 
capacity, and treatment outcomes in newly detected 
cases. Treatment outcomes are particularly important 
because adherence might be lower in patients identiﬁ ed 
in active screening without preselection than in those 
detected passively, potentially limiting the eﬀ ect of 
intensiﬁ ed case ﬁ nding on the control of tuberculosis. 
The purpose of this systematic review is to examine 
strategies of intensiﬁ ed case ﬁ nding as outlined in the 
WHO 3Is policy.7 Key outcomes of interest in reviewed 
published work include the prevalence of tuberculosis in 
speciﬁ cally targeted groups, the associated NNS, the 
screening strategy used, cost-eﬀ ectiveness, and treatment 
outcomes of newly detected cases.
Methods
Search strategy and selection criteria
The searches and review process were done according to 
a prespeciﬁ ed protocol. We aimed to identify studies 
using intensiﬁ ed case ﬁ nding in resource-limited settings. 
Both cross-sectional and cohort studies published in all 
languages were eligible for inclusion. We searched 
available systematic and narrative reviews for active case 
ﬁ nding and household-contact investigations. Two 
systematic reviews were identiﬁ ed.8,14 Additionally, we 
searched Medline, EmBase, and Global Health for reports 
published through April, 2009, and African Health Line 
up to March, 2009. Search strategies are presented in the 
webappendix. The search strategy for African Health Line 
included “tuberculosis”, “active or intensiﬁ ed or enhanced 
case ﬁ nding”, “prisons or prisoners”, “mines or miners”, 
“homosexuals”, “voluntary counselling”, and “testing or 
VCT”. Abstract books covering the years 1998–2008 of the 
World Conference on Lung Health published by the 
International Union Against Tuberculosis and Lung 
Disease were hand searched. Reference lists of primary 
studies, reviews, and editorials identiﬁ ed by the above 
methods were hand searched. Experts in the specialty 
were contacted for additional publications.
According to the WHO 3Is policy, regular screening for 
tuberculosis is recommended in groups at high risk of 
infection with HIV, individuals infected with HIV, groups 
living in congregate settings, and in contacts of people 
with tuberculosis. The strategy to be used in contact 
tracing is not explicitly described in the policy, and so for 
the purposes of this Review we focused on contact tracing 
studies in populations where the prevalence of HIV was 
at least 5% among notiﬁ ed cases of tuberculosis. We also 
deﬁ ned groups at high risk for infection with HIV as 
prisoners, commercial sex workers, injecting drug users, 
men who have sex with men, and individuals attending 
voluntary counselling and testing centres and sexually 
transmitted disease clinics. Even though the 3Is policy 
does not recommend mass screening on a population 
level, it is arguable that general populations in 
sub-Saharan Africa constitute groups at high risk for 
HIV. Thus, surveys of the prevalence of tuberculosis in 
populations with a prevalence of HIV of greater than 5% 
were included in this Review. 
Our Review was limited to studies published from 1993 
(when WHO declared tuberculosis to be a worldwide 
emergency) to 2009.15 We only included studies in 
low-income and middle-income countries, as deﬁ ned by 
the World Bank in 2008,16 and studies that screened a 
minimum of 100 people. We excluded editorials, case 
studies, case reports, studies screening only children 
younger than 15 years, and studies with unclear screening 
strategies or denominators. However, we included 
contact-tracing studies that screened both adults and 
children. 
The initial database created from the electronic searches 
was compiled, duplicate citations were eliminated, and 
citations were screened by title and abstract to capture 
potentially relevant studies. The full text of these studies 
was obtained and reviewed according to inclusion and 
exclusion criteria. Screening of full text from citations 
found to be potentially relevant was done by two reviewers 
(KK and SDL). Queries on study design and study quality 
were discussed with another reviewer (JRG), and studies 
were only included if there was consensus.
Data extraction and analysis
Where data from a single study were present in multiple 
publications, these data were compiled. The data 
See Online for webappendix
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extraction form was adapted from the STROBE statement 
checklist.17 Variables recorded included title, objective, 
year of study, year of publication, study design, setting, 
eligibility criteria of participants, sources and methods of 
selection of participants, screening strategy, diagnostic 
criteria for tuberculosis, internal and external quality 
checks, eﬀ orts to reduce bias, numbers of individuals at 
each stage of the study, number of cases of tuberculosis, 
prevalence of tuberculosis, and funding source. One 
reviewer (KK) extracted data from all eligible studies. A 
second reviewer (SDL) independently extracted data from 
20 of the included studies. The ratings given by the two 
reviewers were in complete agreement. 
Primary outcome of interest was the yield of intensiﬁ ed 
case ﬁ nding as deﬁ ned by the prevalence of newly 
microbiologically conﬁ rmed or clinically or radiologically 
diagnosed cases of tuberculosis in the target population 
and the NNS to ﬁ nd one new case of tuberculosis. The 
NNS was calculated as the reciprocal of the prevalence of 
newly diagnosed tuberculosis. Secondary outcomes of 
interest were the screening strategy used, treatment 
outcomes, and cost per case found.
All analyses were done in Stata 10. We report medians 
and ranges; weighted medians were used to compare 
yield of screening for tuberculosis in individuals infected 
with HIV by use of diﬀ erent screening strategies. We 
used inverse-variance-weighted metaregression to 
investigate the association between yield of intensiﬁ ed 
case ﬁ nding and country prevalence of tuberculosis, 
prevalence of HIV in the general population, screening 
strategies, availability of culture, and HIV status of the 
study population.18,19 Country prevalence estimates for 
tuberculosis and HIV were obtained from the WHO 
Global Health Atlas.20 We analysed residuals to check 
model assumptions.
Results
83 publications (69 published papers and 14 abstracts) 
published between January, 1994, and April, 2009, were 
eligible for inclusion (ﬁ gure 1). After compiling multiple 
publications of the same study a total of 78 studies were 
included. Most studies (55) were published in the past 
6 years, with the largest numbers of publications being 
in 2008 (12) and 2007 (13).
Of those studies included, 30 were from congregate 
settings, ten from voluntary counselling and testing 
settings, three from programmes preventing mother-to-
child transmission (PMTCT), 16 from antiretroviral 
therapy and medical clinics, ten contact tracing studies, 
eight population-based surveys of the prevalence of 
tuberculosis, and one study among men who have sex 
with men and injecting drug users. Most studies were 
from sub-Saharan Africa (41); others were from the 
Americas (22) and Asia (19).
The proportion of eligible individuals who agreed to 
participate in these studies was variable, ranging from 
40–100% in prisons, 44–100% in voluntary counselling 
and testing and PMTCT settings, 35–100% in clinic-
based settings, 83–100% in contact tracing studies, and 
66–100% in population-based surveys (webappendix). 
Clear external and internal quality-control procedures for 
microbiological and radiological investigations were only 
recorded in three studies in congregate settings, two 
studies in clinic-based settings, one study in household 
contacts, and four population-based surveys. 
The prevalence of newly diagnosed tuberculosis varied 
greatly between diﬀ erent countries and speciﬁ c target 
populations (table 1). The minimum was 0·01% in a 
contact-tracing study from Peru and the maximum was 
24·7% in an antiretroviral therapy clinic in South Africa. 
Median NNS varied greatly, ranging from 148 in 
population-based prevalence surveys to just 12 in 
voluntary counselling and testing services and in 
antiretroviral therapy and medical clinics (table 1). 
Results of studies of intensiﬁ ed case ﬁ nding in prisons, 
psychiatric hospitals, mines, and refugee camps are 
presented in the webappendix. HIV status was established 
in three of 30 studies and screening strategies varied 
substantially, with most using an initial questionnaire on 
the symptoms of tuberculosis followed by diagnostic 
testing of people suspected to have tuberculosis. Three of 
six studies in miners combined the screening of symptoms 
with chest radiology to deﬁ ne those people suspected of 
having tuberculosis, whereas the other three studies used 
sputum microbiology irrespective of symptoms. 
The median NNS in all prisons was 40 (range 14–833), 
but was lower in studies in prisons in sub-Saharan Africa 
 8353 potentially relevant citations identiﬁed from electronic databases
 73 potentially relevant citations identiﬁed from reference lists
 35 potentially relevant citations identiﬁed from conference abstract books
247 articles selected for full test review
69 publications and 14 abstracts included
8214 excluded after ﬁrst screen
 2664 duplicates
 5550 on basis of title or abstract
164 excluded after ﬁrst screen
 32 population-based surveys of prevalence of tuberculosis with 
  HIV prevalence less than 5%
 5 contact screening studies with prevalence of HIV in incident 
  cases of tuberculosis less than 5%
 9 studies in subpopulations with prevalence of HIV less than 5%
 27 retrospective studies
 2 studies limited to individuals not infected with HIV
 29 reviews, commentaries, editorials
 8 studies in high-income countries
 11 studies in children
 2 tuberculin skin test surveys
 3 sample size less than 100
 29 unclear study design
 7 already published
Figure 1: Study selection process
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(median 28, range 14–55; table 1). The prevalence of HIV 
was established in only one study in a Brazilian prison 
(25%).41
Studies in miners and ex-miners found a median NNS 
of 43 (range 20–86; table 1). In one study enrolling only 
miners infected with HIV, the prevalence of newly 
diagnosed tuberculosis was 4·9%.46 Of the remaining ﬁ ve 
studies only one study tested miners for HIV, and 
reported a prevalence of 27%.47
Most studies in voluntary counselling and testing 
clinics, PMTCT programmes, and in groups at high risk 
of infection with HIV (men who have sex with men and 
injecting drug users)100 identiﬁ ed people suspected of 
having tuberculosis by screening their symptoms before 
using diagnostic tests (webappendix). Sputum microscopy 
was the only microbiological test available in half of the 
studies. The median NNS was 12 (range 4–123) in 
voluntary counselling and testing settings and 44 (range 
29–47) in PMTCT settings (table 1).
Intensiﬁ ed case ﬁ nding was done as part of isoniazid 
preventive therapy programmes or before antiretroviral 
therapy was started, in individuals infected with HIV 
accessing health care or enrolled in home-based care 
services. Half of the studies used questionnaires on the 
symptoms of tuberculosis as the ﬁ rst step before 
microbiological investigations for symptomatic individuals 
(webappendix). Median NNS was 12 (range 4–71; table 1). 
Results from contact-tracing studies (webappendix) are 
not directly comparable with results from other settings 
since most studies included children. Microbiological 
examinations were only done in individuals that were 
symptomatic or in individuals with positive tuberculin 
skin tests. Median NNS was 48 (range 7–10 000; table 1).
Five of eight population-based surveys of the prevalence 
of tuberculosis in settings with high prevalence of HIV 
used a step-wise screening approach with screening for 
the symptom of tuberculosis preceding microbiological 
examination. The remaining three studies examined the 
sputum in all individuals irrespective of symptoms 
(webappendix). Median NNS was 148 (range 29–5000; 
table 1).
Figure 2 summarises data from 47 studies in countries 
with generalised epidemics of HIV. More than half the 
studies (27) reported a prevalence of newly diagnosed 
tuberculosis in the screened population of greater than 
3% (NNS less than 33). Excluding population surveys, 
two-thirds (26 of 39) of the studies reported prevalence of 
newly diagnosed tuberculosis of greater than 3%.
The screening strategies varied widely across the 
studies. Symptom screening was used in all but one of 
the prison studies, screening of mine workers invariably 
included chest radiography, and all contact-screening 
studies used symptom screening and assessment of 
responses to the tuberculin skin test. Symptom 
questionnaires were diverse, ranging from any kind of 
Number 
of studies
Regions represented Median prevalence of newly 
diagnosed tuberculosis (range)
Median number needed 
to screen (range)
Congregate settings (all)21–50 30 Africa, Asia, the Americas 2·2% (0·1–7·2) 45 (14–833)
Congregate settings (prisons)21–41 21 Africa, Asia, the Americas 2·5% (0·1-7·2) 40 (14–833)
Congregate settings (prisons)27–33 7 Sub-Saharan Africa 3·6% (1·8–7·2) 28 (14–55)
Congregate settings (mines)43–48 6 Africa, Asia 2·3% (1·2–5·0) 43 (20–86)
Voluntary counselling and testing services51–61 10 Africa, Asia, the Americas 8·5% (0·8–23·6) 12 (4–123)
Prevention of mother-to-child transmission services62–64 3 Africa, Asia 2·3% (2·1–3·5) 44 (29–47)
Antiretroviral therapy and medical clinics9,10,65–81 16 Africa, Asia, the Americas 8·2% (1·4–24·7) 12 (4–71)
Antiretroviral therapy and medical clinics9,10,70–77 8 Sub-Saharan Africa 8·6% (3·6–24·7) 12 (4–28)
Contact tracing82–91 10 Africa, Asia, the Americas 2·2% (0·01–14·5) 45 (7–10 000)
Population-based surveys11,92–99 8 Sub-Saharan Africa 0·7% (0·02–3·5) 148 (29–5000)
Table 1: Tuberculosis prevalence and the number needed to screen to identify one new case in diﬀ erent target groups
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Figure 2: Prevalence of tuberculosis among individuals screened in diﬀ erent settings in countries with 
generalised epidemics of HIV
VCT=voluntary counselling and testing. PMTCT=prevention of mother-to-child transmission.
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respiratory symptoms to various durations of productive 
cough plus or minus weight loss, night sweats, fatigue, 
fever, and haemoptysis. Similarly, the number and timing 
of sputum samples varied substantially.
In 12 studies that included only individuals infected 
with HIV, sputum examination was done irrespective of 
symptoms. Nine of these studies were done in 
antiretroviral therapy services, medical clinics, or 
home-based HIV care programmes and the remaining 
three were done in voluntary counselling and testing 
centres. All but one of these studies did both smears and 
cultures. 17 studies screened individuals infected with 
HIV with symptom-based questionnaires preceding 
sputum examination of people suspected to have 
tuberculosis. These studies were done in antiretroviral 
therapy and medical clinics (seven studies), voluntary 
counselling and testing centres (seven), and PMTCT 
programmes (three). Of these 17 studies, seven only did 
sputum smears whereas ten did both smears and 
cultures. In the subset of studies in which both smears 
and cultures were done, the prevalence of newly 
diagnosed tuberculosis in individuals infected with HIV 
was slightly lower (weighted median 9·8%) in studies 
only investigating preselected people suspected to have 
tuberculosis on the basis of symptom screening 
compared with studies doing sputum smears and 
cultures on everyone irrespective of symptoms (weighted 
median 11·6%).
Because the strategies and yield of intensiﬁ ed case 
ﬁ nding were very heterogeneous between studies done 
in diﬀ erent countries and patient groups, we sought to 
identify variables independently associated with the yield 
of tuberculosis by use of metaregression analysis (tables 2 
and 3). 
Of the 78 studies included in the analysis, some target 
populations included only individuals infected with HIV 
(30 studies), whereas the remainder included individuals 
with and without HIV (congregate settings, contact 
screening, and population-based prevalence studies). 
Metaregression analysis was therefore stratiﬁ ed with 
regards to HIV status of the screened population. 
In the univariate analysis of studies with patients with 
mixed or unknown HIV-status (48 studies), national 
prevalence of tuberculosis and HIV, screening strategy of 
microbiological investigations in all individuals, and 
availability of culture were not associated with yield of 
screening (table 2). 
By contrast, univariate analysis of studies that only 
included individuals infected with HIV (30 studies) 
found that both the use of symptom prescreening and 
the country prevalence of tuberculosis were associated 
with the detected yield of tuberculosis (table 3). However, 
the availability of culture and the national prevalence of 
HIV were not associated with the detected yield of 
tuberculosis. Multivariate analysis showed that 
microbiological sputum examination (smear or culture) 
on all individuals without prior selection on the basis of 
screening for symptoms detected an additional four cases 
per 100 individuals screened (p=0·05). Furthermore, an 
increment in country prevalence of tuberculosis of 
100 cases of tuberculosis per 100 000 population was 
associated with an additional yield of one case per 
100 individuals screened (p=0·03). 
Restricting the analysis to studies in individuals 
infected with HIV routinely doing both sputum smears 
and cultures as part of the microbiological investigations 
(22 studies) showed similar results with regards to eﬀ ect 
estimate for symptom screening (slope 3·6, 95% CI 
–0·9 to 8·0). 
Estimates of national prevalence of tuberculosis are 
infrequently on the basis of prevalence survey data, they 
are instead derived from estimates of the incidence of 
tuberculosis. In view of this and that national estimates 
of incidence of tuberculosis are more readily available, 
we repeated the metaregression analysis with the 
inclusion of estimated incidence of tuberculosis rather 
than estimated prevalence. In this model, an increment 
in country incidence of tuberculosis of 100 cases of 
tuberculosis per 100 000 people was associated with an 
additional yield of 0·7 case per 100 individuals screened 
(p=0·04). 
Only three studies reported treatment outcomes of 
individuals diagnosed with tuberculosis during 
intensiﬁ ed case ﬁ nding. In a population-based study in 
South Africa, only 13 (56%) of 23 people actively detected 
Slope (95% CI) 
in univariate 
analysis
p value in 
univariate 
analysis
Slope (95% CI) 
in multivariate 
analysis
p value in 
multivariate 
analysis
Country prevalence of tuberculosis* 1·1 (0·2 to 2·0) 0·02 1 (0·1 to 1·9) 0·03
Country prevalence of HIV† 1·3 (–17·5 to 43·1) 0·4 ·· ··
Availability of culture‡ 2·0 (–2·7 to 6·7) 0·39 ·· ··
Symptom screening§ 4·3 (0·34 to 8·2) 0·03 3·7 (0·05 to 7·4) 0·05
*One unit increase=100 cases of tuberculosis per 100 000 people. †One unit increase=10% increase in prevalence. 
‡Coded as 0 if no culture available or 1 if culture available. §Coded as 0 if symptom screening used to identify people 
suspected to have tuberculosis or 1 if all individuals screened with sputum smears or culture.
Table 3: Factors potentially aﬀ ecting yield of intensiﬁ ed case screening in populations with individuals 
infected with HIV
Slope (95% CI) p value
Country prevalence of tuberculosis* –0·2 (–0·5 to 0·1) 0·21
Country prevalence of HIV† –4·8 (–12·8 to 3·3) 0·24
Availability of culture‡ –0·3 (–1·6 to 1·1) 0·65
Symptom screening§ –0·3 (–2·4 to 1·8) 0·77
*One unit increase=100 cases of tuberculosis per 100 000 people. †One unit 
increase=10% increase in prevalence. ‡Coded as 0 if no culture available or 1 if 
culture available. §Coded as 0 if symptom screening used to identify people 
suspected to have tuberculosis or 1 if all individuals screened with sputum smears 
or culture.
Table 2: Univariate analysis of factors potentially aﬀ ecting yield of 
intensiﬁ ed case screening in populations with mixed or unknown HIV 
status
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with tuberculosis completed treatment.97 Among 
24 women infected with HIV in India diagnosed with 
tuberculosis after giving birth, 21 started treatment for 
tuberculosis and 17 (70%) were either cured or still 
receiving treatment at time of analysis.62 In the 
Côte d’Ivoire, of 134 prisoners diagnosed with 
tuberculosis, 99 (74%) were cured, 32 (24%) died, and in 
three (2%) treatment failed.28 None of these studies had 
data for treatment outcome available for those diagnosed 
passively.
None of the studies included in this systematic review 
did costing or cost-eﬀ ectiveness analyses. 
Discussion
Intensiﬁ ed case ﬁ nding is a key component of the WHO 
3Is policy that aims to strengthen the public health 
response to the epidemic of HIV-associated tuberculosis—
a major stumbling block to attainment of the sixth 
Millennium Development Goal targets for worldwide 
control of tuberculosis. In this systematic review, we 
included 78 studies from 27 diﬀ erent countries, most 
from sub-Saharan Africa. The yield of screening for 
tuberculosis varied greatly between countries and target 
populations, with the highest yields in antiretroviral 
therapy and voluntary counselling and testing clinics, 
and the lowest yields in population-based surveys of the 
prevalence of tuberculosis. Our analysis showed that the 
yield of intensiﬁ ed case ﬁ nding depends strongly on the 
prevalence of HIV of the target population, the national 
prevalence of tuberculosis, and the screening strategy. In 
studies only screening individuals infected with HIV, 
each increment in national prevalence of tuberculosis of 
100 cases per 100 000 people resulted in an additional 
yield of one case per 100 individuals screened. 
Furthermore, substantially higher yields can be achieved 
if all individuals have sputum examination irrespective 
of symptoms. These data will help inform implementation 
of intensiﬁ ed case ﬁ nding policies.
Using a process of passive case ﬁ nding, the directly 
observed short-course strategy has failed to control rising 
incidence rates of HIV-associated tuberculosis in 
resource-limited settings,101 and many patients dying with 
HIV/AIDS have tuberculosis that has not been diagnosed.102 
Intensiﬁ ed case ﬁ nding aims to increase case-detection 
rates and shorten the time to diagnosis of tuberculosis, 
thereby reducing morbidity and mortality and shortening 
the period of infectiousness, and it should, in turn, reduce 
the risk of transmitting tuberculosis in community and 
health-care settings.103–106 However, intensiﬁ ed case ﬁ nding 
is more resource-intensive than passive case ﬁ nding and a 
number of key issues must be considered. These issues 
include the populations to be targeted, the NNS to identify 
each new case, the screening strategy, laboratory capacity, 
operational feasibility, outcomes of newly identiﬁ ed cases 
of tuberculosis, and costs. 
Prevalence of newly diagnosed tuberculosis and 
subsequently the NNS varied widely between diﬀ erent 
target populations with a median of 148 (range 29–5000) 
in population-based surveys, 45 (7–10 000) in contact 
tracing studies, 43 (20–86) in mines, 40 (14–833) in 
prisons, 12 (4–123) in voluntary counselling and testing, 
44 (29–47) in PMTCT settings, and 12 (4–71) in 
antiretroviral therapy or medical clinics. 
The upper limit for the NNS at which intensiﬁ ed case 
ﬁ nding is deemed useful might diﬀ er between target 
populations. For example, the importance of identiﬁ cation 
of tuberculosis among prisoners is high because of the 
high probability of transmission to other prisoners, and 
among pregnant women it is high in view of the 
probability of transmission to unborn children.107,108 
Intensiﬁ ed case ﬁ nding might also be prioritised in 
settings with known high prevalence of drug-resistant 
tuberculosis, such as prisons. 
Guidelines originating from the era before HIV assume 
that state programmes for tuberculosis in resource-limited 
settings should screen an average of ten people suspected 
to be infected to identify one smear-positive case to 
prevent laboratory overload.109 Laboratory equipment and 
consumables for tuberculosis are allocated on this basis. 
More recent experience has shown that in practice an 
average of seven people newly suspected of having 
tuberculosis are screened to identify one sputum 
smear-positive case of tuberculosis, although this number 
varies widely (3·3–20).110 Irrespective of the speciﬁ c target 
populations, we found that intensiﬁ ed case ﬁ nding will 
need more resources. Scale-up will only be possible if 
laboratory capacity increases in parallel and quality 
assurance procedures are adequate. 
The eﬀ ectiveness of intensiﬁ ed case ﬁ nding depends 
on the screening strategy used. In studies of groups of 
patients infected with HIV, intensiﬁ ed case ﬁ nding with 
microbiological (sputum smear or culture) investigation 
in all patients irrespective of symptoms detected an 
additional four cases per 100 individuals screened. This 
ﬁ nding is consistent with the observation that a substantial 
proportion of individuals infected with HIV have 
subclinical tuberculosis when screened actively.10–13,96
The WHO 3Is strategy recommends repeated intensiﬁ ed 
case ﬁ nding in individuals infected with HIV. However, 
no empirical data exist on the use of this type of serial 
screening, especially in a population of people infected 
with HIV. Serial screening with mass radiography in 
Czechoslovakia in 1961–72 showed a decrease in 
prevalence of newly diagnosed tuberculosis from 36 cases 
per 100 000 people to 18 cases per 100 000 people.111 Thus, 
a similar eﬀ ect might happen with serial intensiﬁ ed case 
ﬁ nding in individuals infected with HIV, although the 
yield in groups of patients infected with HIV is also likely 
to vary in parallel with changes to the degree of 
immunodeﬁ ciency. Studies establishing the yield obtained 
during serial screening, the optimum screening interval, 
and the implications for laboratory capacity are needed.
The diagnosis of tuberculosis by active screening is 
typically less advanced than the diagnosis of disease 
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during passive case ﬁ nding.105,112,113 Patients with less 
advanced disease might, in turn, have lower numbers of 
adherence to treatment, potentially resulting in poorer 
treatment outcomes among those whose disease is 
detected by intensiﬁ ed case ﬁ nding. However, data on 
treatment outcomes are scarce. A study from South Africa 
found that the rates of treatment for tuberculosis were 
low (73%) among actively detected cases.112 Similar results 
were reported from population-based prevalence surveys 
from India and Nepal showing higher treatment refusal 
and default rates in actively compared with passively 
detected cases of tuberculosis.114,115 Therefore, intensiﬁ ed 
case ﬁ nding must be accompanied with eﬀ ective means 
of ensuring that newly identiﬁ ed cases of tuberculosis 
are eﬀ ectively treated.
Our metaregression analysis found that each increment 
in national prevalence of tuberculosis of 100 cases per 
100 000 people was associated with an additional yield of 
about one case per 100 screened individuals infected with 
HIV. These data provide some basis for estimating the 
potential beneﬁ ts of intensiﬁ ed case ﬁ nding in diﬀ erent 
countries. Although none of the studies presented in 
this Review investigated cost-eﬀ ectiveness, modelling 
suggests that population-based intensiﬁ ed case ﬁ nding 
symptom screening every 7 years would be highly 
cost-eﬀ ective in sub-Saharan Africa, averting 29 million 
cases of tuberculosis and 13 million deaths by 2050.116 
One study from South Africa estimated a cost of US$12 
for each person screened for tuberculosis in the 
community health centre and $7 per person in the 
primary health-care clinic. The cost per case of 
tuberculosis prevented was estimated to be $323–366, 
assuming that 25 cases of tuberculosis would be 
prevented for every 100 cases of tuberculosis detected by 
intensiﬁ ed case ﬁ nding.117 However, more country-speciﬁ c 
and setting-speciﬁ c data on costs are needed to inform 
policy makers. 
Our systematic review has several strengths. Publication 
bias was limited by the use of a prespeciﬁ ed comprehensive 
search strategy and review process that included published 
and unpublished studies without language restrictions. 
Reproducibility of data extraction was veriﬁ ed for a subset 
of studies. Heterogeneity of study results was investigated 
using metaregression analysis. This Review, which is 
primarily descriptive, also has limitations. Assessment of 
ascertainment bias at study level was limited because of 
the lack of reporting of internal and external quality-control 
procedures. Furthermore, variable uptake in the 
proportions of eligible individuals who agreed to 
participate in these studies might have inﬂ uenced 
reported prevalence of tuberculosis. Regression analyses 
could be subject to residual confounding.
Conclusion
In countries with high prevalence of tuberculosis, 
intensiﬁ ed case ﬁ nding among individuals infected with 
HIV identiﬁ es a high yield of people with tuberculosis 
and the yield is signiﬁ cantly increased if all such 
individuals are screened microbiologically without 
preselection on the basis of the screening of symptoms. 
The data presented might help the prioritisation of 
speciﬁ c groups for intensiﬁ ed case ﬁ nding. Scaling-up of 
intensiﬁ ed case ﬁ nding will need development of 
standardised screening algorithms, substantial increases 
in the capacities of quality-assured laboratories, and 
eﬃ  cient systems to ensure that people newly diagnosed 
with tuberculosis receive adequate treatment. Concerted 
action in tandem with further research might help 
develop this policy as an important method to accelerate 
progress towards the tuberculosis targets within the sixth 
Millennium Development Goal.
Contributors 
KK did the searches of published work and data extraction with input 
from SDL and JRG. The meta-regression analysis was done by KK with 
input from RMGJH and JRG. KK and SDL wrote the paper with input 
from RMGJH, JRG, LGB, and RW.
Conﬂ icts of interest
We declare that we have no conﬂ icts of interest.
Acknowledgments 
SDL and KK are funded by the Wellcome Trust, London, UK. RW and 
LGB are funded in part by the National Institutes of Health (NIH) 
through a CIPRA grant 1U19AI53217-01 and RO1 grant (A1058736-01A1). 
JRG and RMGJH are funded by the London School of Hygiene and 
Tropical Medicine (HEFCE funding). The funding sources played no 
part in the decision to publish these data. 
References
1 UN. The millennium development goals report 2008. New York: 
United Nations, 2008: 32–34. http://mdgs.un.org/unsd/mdg/
Resources/Static/Products/Progress2008/MDG_Report_2008_
En.pdf#page=34 (accessed Dec 17, 2009).
2 WHO. Global tuberculosis control 2009: epidemiology, strategy, 
ﬁ nancing. Geneva: World Health Organization, 2009. http://www.
who.int/tb/publications/global_report/2009/pdf/full_report.pdf 
(accessed Dec 17, 2009).
3 UNAIDS/WHO. Guidelines for second generation hiv surveillance. 
Geneva: World Health Organization, 2000. http://www.searo.who.
int/LinkFiles/Facts_and_Figures_01_2ndgen_Eng.PDF 
(accessed Dec 17, 2009).
4 WHO. Interim policy on collaborative TB/HIV activities. Geneva: 
World Health Organization, 2004. http://whqlibdoc.who.int/
hq/2004/WHO_HTM_TB_2004.330.pdf (accessed Dec 17, 2009).
5 WHO. Joint HIV/tuberculosis interventions. Geneva: World Health 
Organization, 2002. http://www/who.int/hiv/topics/tb/
tuberculosis/en (accessed Dec 17, 2009).
6 WHO. Towards universal access: scaling up priority HIV/AIDS 
interventions in the health sector. Geneva: World Health 
Organization, 2007. http://whqlibdoc.who.int/publications/2007/97
89241595391_eng.pdf (accessed Dec 17, 2009).
7 WHO. WHO three I’s meeting. Geneva: World Health 
Organization, 2008. http://www.who.int/hiv/pub/meetingreports/
WHO_3Is_meeting_report.pdf (accessed Dec 17, 2009).
8 Golub JE, Mohan CI, Comstock GW, Chaisson RE. Active case 
ﬁ nding of tuberculosis: historical perspective and future prospects. 
Int J Tuberc Lung Dis 2005; 9: 1183–203.
9 Reid MJ, Shah NS. Approaches to tuberculosis screening and 
diagnosis in people with HIV in resource-limited settings. 
Lancet Infect Dis 2009; 9: 173–84.
10 Mtei L, Matee M, Herfort O, et al. High rates of clinical and 
subclinical tuberculosis among HIV-infected ambulatory subjects in 
Tanzania. Clin Infect Dis 2005; 40: 1500–07.
11 Lawn SD, Edwards SD, Kranzer K, Vogt M, Bekker LG, Wood R. 
Urine lipoarabinomannan assay for tuberculosis screening before 
antiretroviral therapy diagnostic yield and association with immune 
reconstitution disease. AIDS 2009; 23: 1875–80.
Search strategy 
and selection 
criteria
These are described 
in detail in the 
Methods section
100 www.thelancet.com/infection   Vol 10   February 2010
Review
12 Wood R, Middelkoop K, Myer L, et al. Undiagnosed tuberculosis in 
a community with high HIV prevalence: implications for 
tuberculosis control. Am J Respir Crit Care Med 2007; 175: 87–93.
13 Swaminathan S, Paramasivan CN, Kumar SR, Mohan V, 
Venkatesan P. Unrecognised tuberculosis in HIV-infected patients: 
sputum culture is a useful tool. Int J Tuberc Lung Dis 2004; 8: 896–98.
14 WHO. TB: a global emergency. Geneva: World Health 
Organization, 1994. http://whqlibdoc.who.int/hq/1994/WHO_TB_
94.177.pdf (accessed Dec 17, 2009).
15 World Bank. Data and statistics: country classiﬁ cation. World Bank, 
2009. http://go.worldbank.org/K2CKM78CC0 
(accessed Dec 17, 2009).
16 Morrison J, Pai M, Hopewell PC. Tuberculosis and latent tuberculosis 
infection in close contacts of people with pulmonary tuberculosis in 
low-income and middle-income countries: a systematic review and 
meta-analysis. Lancet Infect Dis 2008; 8: 359–68.
17 von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, 
Vandenbroucke JP. Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) statement: guidelines for 
reporting observational studies. BMJ 2007; 335: 806–08.
18 Thompson SG, Higgins JP. How should meta-regression analyses 
be undertaken and interpreted? Stat Med 2002; 21: 1559–73.
19 Berkey CS, Hoaglin DC, Mosteller F, Colditz GA. A random-eﬀ ects 
regression model for meta-analysis. Stat Med 1995; 14: 395–411.
20 WHO. Global health atlas. World Health Organization; 2009. 
http://apps.who.int/globalatlas/dataQuery/default.asp 
(accessed Dec 17, 2009).
21 Aerts A, Habouzit M, Mschiladze L, et al. Pulmonary tuberculosis 
in prisons of the ex-USSR state Georgia: results of a nation-wide 
prevalence survey among sentenced inmates. Int J Tuberc Lung Dis 
2000; 4: 1104–10.
22 Salek S, Taghizadeh AR, Yazdanpanah M, et al. Case ﬁ nding of 
pulmonary tuberculosis in Ghasr prison. 32nd World Conference 
on Lung Health of the International Union Against Tuberculosis 
and Lung Disease; Paris, France; Nov 1–4, 2001.
23 Askarian M, Karmi A, Sadeghi-Hassanabadi A. Tuberculosis 
among never-jailed drug abusers. East Mediterr Health J 2001; 
7: 461–64.
24 Yazdanpanah M. To assess the pulmonary tuberculosis among 
prisoners. 30th World Conference on Lung Health of the International 
Union Against Tuberculosis and Lung Disease; Madrid, Spain; 
Sept 14–18, 1999.
25 Rao NA. Prevalence of pulmonary tuberculosis in Karachi central 
prison. J Pak Med Assoc 2004; 54: 413–15.
26 Shah SA, Mujeeb SA, Mirza A, Nabi KG, Siddiqui Q. Prevalence of 
pulmonary tuberculosis in Karachi juvenile jail, Pakistan. 
East Mediterr Health J 2003; 9: 667–74.
27 Noeske J, Kuaban C, Amougou G, Piubello A, Pouillot R. 
Pulmonary tuberculosis in the Central Prison of Douala, Cameroon. 
East Afr Med J 2006; 83: 25–30.
28 Koﬃ   N, Ngom AK, Aka-Danguy E, Seka A, Akoto A, Fadiga D. 
Smear positive pulmonary tuberculosis in a prison setting: 
experience in the penal camp of Bouake, Ivory Coast. 
Int J Tuberc Lung Dis 1997; 1: 250–53.
29 Rapid assessment of tuberculosis in a large prison system–Botswana, 
2002. MMWR Morb Mortal Wkly Rep 2003; 52: 250–52.
30 Banerjee A, Harries AD, Mphasa N, Yadid AE, Nyirenda T, 
Salaniponi FM. Prevalence of HIV, sexually transmitted disease and 
tuberculosis amongst new prisoners in a district prison, Malawi. 
Trop Doct 2000; 30: 49–50.
31 Nyangulu DS, Harries AD, Kang’ombe C, et al. Tuberculosis in a 
prison population in Malawi. Lancet 1997; 350: 1284–87.
32 Habeenzu C, Mitarai S, Lubasi D, et al. Tuberculosis and multidrug 
resistance in Zambian prisons, 2000–2001. Int J Tuberc Lung Dis 
2007; 11: 1216–20.
33 Pillay M, Govender K, Reddy S, Roux L, Kagoro H, Sturm AW. 
The prevalence of tuberculosis in a South African prison. 34th 
World Conference on Lung Health of the International Union 
Against Tuberculosis and Lung Disease; Paris, France; 
Oct 29–Nov 2, 2003. Abstract 395-PS
34 Naranbat N, Otgontsetseg D, Nymadawa P, Tsogt G. Tuberculosis in 
Mongolian prisons. 32nd World Conference on Lung Health of the 
International Union Against Tuberculosis and Lung Disease; Paris, 
France; Nov 1–4, 2001.
35 Jittimanee SX, Ngamtrairai N, White MC, Jittimanee S. 
A prevalence survey for smear-positive tuberculosis in Thai prisons. 
Int J Tuberc Lung Dis 2007; 11: 556–61.
36 Sretrirutchai S, Silapapojakul K, Palittapongarnpim P, 
Phongdara A, Vuddhakul V. Tuberculosis in Thai prisons: 
magnitude, transmission and drug susceptibility. 
Int J Tuberc Lung Dis 2002; 6: 208–14.
37 Sanchez AR, Massari V, Gerhardt G, et al. Tuberculosis in 
Rio de Janeiro prisons, Brazil: an urgent public health problem. 
Cad Saude Publica 2007; 23: 545–52 (in Portuguese).
38 Abrahao RM, Nogueira PA, Malucelli MI. Tuberculosis in county 
jail prisoners in the western sector of the city of Sao Paulo, Brazil. 
Int J Tuberc Lung Dis 2006; 10: 203–08.
39 Fournet N, Sanchez A, Massari V, et al. Development and 
evaluation of tuberculosis screening scores in Brazilian prisons. 
Public Health 2006; 120: 976–83.
40 Sanchez A, Gerhardt G, Natal S, et al. Prevalence of pulmonary 
tuberculosis and comparative evaluation of screening strategies in 
a Brazilian prison. Int J Tuberc Lung Dis 2005; 9: 633–39.
41 Ferreira MM, Ferrazoli L, Palaci M, et al. Tuberculosis and HIV 
infection among female inmates in Sao Paulo, Brazil: a prospective 
cohort study. J Acquir Immune Deﬁ c Syndr Hum Retrovirol 1996; 
13: 177–83.
42 Van Duc L, Vree M, Cobelens FG, Phuc LT, Sy DN. High 
tuberculosis prevalence in a psychiatric hospital in Vietnam. 
Int J Tuberc Lung Dis 2008; 12: 686–88.
43 Steen TW, Gyi KM, White NW, et al. Prevalence of occupational 
lung disease among Botswana men formerly employed in the 
South African mining industry. Occup Environ Med 1997; 54: 19–26.
44 Fielding K, Chihota V, lewis J, et al. Factors associated with 
prevalent TB at screening prior to isoniazid preventive therapy. 
39th World Conference on Lung Health of the International Union 
Against Tuberculosis and Lung Disease; Paris, France; Oct 16–20, 
2008. Abstract PS-81838-19.
45 Girdler-Brown BV, White NW, Ehrlich RI, Churchyard GJ. The 
burden of silicosis, pulmonary tuberculosis and COPD among 
former Basotho goldminers. Am J Ind Med 2008; 51: 640–47.
46 Day JH, Charalambous S, Fielding KL, Hayes RJ, Churchyard GJ, 
Grant AD. Screening for tuberculosis prior to isoniazid preventive 
therapy among HIV-infected gold miners in South Africa. 
Int J Tuberc Lung Dis 2006; 10: 523–29.
47 Corbett EL, Charalambous S, Moloi VM, et al. Human 
immunodeﬁ ciency virus and the prevalence of undiagnosed 
tuberculosis in African gold miners. Am J Respir Crit Care Med 
2004; 170: 673–79.
48 Aungkasuvapala N, Juengprasert W, Obhasi N. Silicosis and 
pulmonary tuberculosis in stone-grinding factories in Saraburi, 
Thailand. J Med Assoc Thai 1995; 78: 662–69.
49 Weinstock DM, Hahn O, Wittkamp M, Sepkowitz KA, 
Khechinashvili G, Blumberg HM. Risk for tuberculosis infection 
among internally displaced persons in the Republic of Georgia. 
Int J Tuberc Lung Dis 2001; 5: 164–69.
50 Nelson LJ, Davis AB, McCrann CH, et al. Tuberculosis screening at 
a refugee camp in Botswana 2002–2003. 34th World Conference on 
Lung Health of the International Union Against Tuberculosis and 
Lung Disease; Paris, France; Oct 29–Nov 2, 2003. Abstract 229-PS.
51 Shetty PV, Granich RM, Patil AB, et al. Cross-referral between 
voluntary HIV counselling and testing centres and TB services, 
Maharashtra, India, 2003–2004. Int J Tuberc Lung Dis 2008; 
12 (suppl 1): 26–31.
52 Shah S, Demissie M, Lambert L, et al. Intensiﬁ ed tuberculosis case 
ﬁ nding among HIV-Infected persons from a voluntary counseling 
and testing center in Addis Ababa, Ethiopia. 
J Acquir Immune Deﬁ c Syndr 2009; 50: 537–45.
53 Mugisha B, Bock N, Mermin J, et al. Tuberculosis case ﬁ nding and 
preventive therapy in an HIV voluntary counseling and testing 
center in Uganda. Int J Tuberc Lung Dis 2006; 10: 761–67.
54 Aisu T, Raviglione MC, van Praag E, et al. Preventive chemotherapy 
for HIV-associated tuberculosis in Uganda: an operational assessment 
at a voluntary counselling and testing centre. AIDS 1995; 9: 267–73.
55 Godfrey-Faussett P, Baggaley R, Mwinga A, et al. Recruitment to a 
trial of tuberculosis preventive therapy from a voluntary HIV 
testing centre in Lusaka: relevance to implementation. 
Trans R Soc Trop Med Hyg 1995; 89: 354–58.
www.thelancet.com/infection   Vol 10   February 2010 101
Review
56 Naidoo P, Karpakis B, Maartens G, Schoenman H, Hausler HP. 
Active tuberculosis case-ﬁ nding and isoniazid preventive therapy in 
HIV-positive clients at voluntary counselling and testing centres. 
14th International AIDS Conference; Barcelona, Spain; July 7–12, 
2002. Abstract MoPeB3163.
57 Kanara N, Cain KP, Laserson KF, et al. Using program evaluation to 
improve the performance of a TB-HIV project in Banteay 
Meanchey, Cambodia. Int J Tuberc Lung Dis 2008; 
12 (suppl 1): 44–50.
58 CDC. Screening HIV-infected persons for tuberculosis—Cambodia, 
January 2004–February 2005. MMWR Morb Mortal Wkly Rep 2005; 
54: 1177–80.
59 Chheng P, Tamhane A, Natpratan C, et al. Pulmonary tuberculosis 
among patients visiting a voluntary conﬁ dential counseling and 
testing center, Cambodia. Int J Tuberc Lung Dis 2008; 
12 (suppl 1): 54–62.
60 Espinal MA, Reingold AL, Koenig E, Lavandera M, Sanchez S. 
Screening for active tuberculosis in HIV testing centre. Lancet 1995; 
345: 890–93.
61 Burgess AL, Fitzgerald DW, Severe P, et al. Integration of 
tuberculosis screening at an HIV voluntary counselling and testing 
centre in Haiti. AIDS 2001; 15: 1875–79.
62 Gupta A, Nayak U, Ram M, et al. Postpartum tuberculosis incidence 
and mortality among HIV-infected women and their infants in 
Pune, India, 2002–2005. Clin Infect Dis 2007; 45: 241–49.
63 Kali PB, Gray GE, Violari A, Chaisson RE, McIntyre JA, 
Martinson NA. Combining PMTCT with active case ﬁ nding for 
tuberculosis. J Acquir Immune Deﬁ c Syndr 2006; 42: 379–81.
64 Nachega J, Coetzee J, Adendorﬀ  T, et al. Tuberculosis active 
case-ﬁ nding in a mother-to-child HIV transmission prevention 
programme in Soweto, South Africa. AIDS 2003; 17: 1398–400.
65 Swaminathan S, Ramachandran R, Baskaran G, et al. Risk of 
development of tuberculosis in HIV-infected patients. 
Int J Tuberc Lung Dis 2000; 4: 839–44.
66 Dhungana GP, Ghimire P, Sharma S, Rijal BP. Characterization of 
mycobacteria in HIV/AIDS patients of Nepal. 
JNMA J Nepal Med Assoc 2008; 47: 18–23.
67 Dhungana GP, Ghimire P, Sharma S, Rijal BP. Tuberculosis 
co-infection in HIV infected persons of Kathmandu. 
Nepal Med Coll J 2008; 10: 96–99.
68 Khun KE, Tamura M, Yous BH, I. O, Mao TE. New TB screening 
service for poeple living with HIV/AIDS (PLWHA) in Phnom Penh. 
33th World Conference on Lung Health of the International Union 
Against Tuberculosis and Lung Disease; Montreal, Canada; 
Oct 6–10, 2002. Abstract 111-PD.
69 Kimerling ME, Schuchter J, Chanthol E, et al. Prevalence of 
pulmonary tuberculosis among HIV-infected persons in a home 
care program in Phnom Penh, Cambodia. Int J Tuberc Lung Dis 
2002; 6: 988–94.
70 Ngowi BJ, Mﬁ nanga SG, Bruun JN, Morkve O. Pulmonary 
tuberculosis among people living with HIV/AIDS attending care and 
treatment in rural northern Tanzania. BMC Public Health 2008; 8: 341.
71 Bakari M, Arbeit RD, Mtei L, et al. Basis for treatment of 
tuberculosis among HIV-infected patients in Tanzania: the role of 
chest x-ray and sputum culture. BMC Infect Dis 2008; 8: 32.
72 Nakanjako D, Mwesigire D, Wanyenze R, et al. Reinforcement of 
TB screening identiﬁ es a high burden of pulmonary tuberculosis 
among HIV/AIDS patients in the Mulago Immune Suppression 
Clinic, Uganda. 4th IAS Conference on HIV Pathogenesis, 
Treatment and Prevention; Sydney, Australia; July 22–25, 2007. 
73 Moore D, Liechty C, Ekwaru P, et al. Prevalence, incidence and 
mortality associated with tuberculosis in HIV-infected patients 
initiating antiretroviral therapy in rural Uganda. AIDS 2007; 
21: 713–19.
74 Were W, Moore D, Ekwaru P, et al. A simple screening tool for 
active tuberculosis in HIV-infected adults receiving antiretroviral 
treatment in Uganda. Int J Tuberc Lung Dis 2009; 13: 47–53.
75 Gasana M, Vandebriel G, Kabanda G, et al. Integrating tuberculosis 
and HIV care in rural Rwanda. Int J Tuberc Lung Dis 2008; 
12 (suppl 1): 39–43.
76 Bassett I, Chetty S, Wand B, et al. Intensive TB screening for 
HIV-infected patients ready to start ART in Durban, South Africa: 
limitations of WHO guidelines. 16th Conference on Retroviruses 
and Opportunistic Infections; Montreal, Canada; Feb 8–11, 2009. 
77 Mohammed A, Ehrlich R, Wood R, Cilliers F, Maartens G. 
Screening for tuberculosis in adults with advanced HIV infection 
prior to preventive therapy. Int J Tuberc Lung Dis 2004; 8: 792–95.
78 Reddy KP, Brady MF, Gilman RH, et al. MODS for tuberculosis 
screening prior to isoniazid preventive therapy in HIV-infected 
persons. 39th World Conference on Lung Health of the 
International Union Against Tuberculosis and Lung Disease; Paris, 
France; Oct 16–20, 2008. Abstract PS-81628-18.
79 Silva RM, Teixeira PJ, Moreira JdS. Induced sputum for the 
diagnosis of lung disease in HIV-positive patients. J Bras Pneumol 
2004; 30: 452–58.
80 Murcia-Aranguren MI, Gomez-Marin JE, Alvarado FS, et al. 
Frequency of tuberculous and non-tuberculous mycobacteria in 
HIV infected patients from Bogota, Colombia. BMC Infect Dis 2001; 
1: 21.
81 Crespo MP, Heli Corral R, Alzate A, Carrasquilla G, Sanchez N. 
Mycobacterial infections in HIV-infected patients in Cali, Colombia. 
Rev Panam Salud Publica 1999; 6: 249–55 (in Spanish).
82 Kuaban C, Koulla-Shiro S, Lekama Assiene T, Hagbe P. 
Tuberculosis screening of patient contacts in 1993 and 1994 in 
Yaounde, Cameroon. Med Trop (Mars) 1996; 56: 156–58 (in French).
83 Jackson-Sillah D, Hill PC, Fox A, et al. Screening for tuberculosis 
among 2381 household contacts of sputum-smear-positive cases in 
The Gambia. Trans R Soc Trop Med Hyg 2007; 101: 594–601.
84 Diatta A, Toure NO, Kane YD, et al. Familial tuberculosis: tracing 
the contacts of an infectious case. Rev Mal Respir 2007; 24: 32–40 
(in French).
85 Guwatudde D, Nakakeeto M, Jones-Lopez EC, et al. Tuberculosis in 
household contacts of infectious cases in Kampala, Uganda. 
Am J Epidemiol 2003; 158: 887–98.
86 Zachariah R, Spielmann MP, Harries AD, et al. Passive versus 
active tuberculosis case ﬁ nding and isoniazid preventive therapy 
among household contacts in a rural district of Malawi. 
Int J Tuberc Lung Dis 2003; 7: 1033–39.
87 Suggaravetsiri P, Yanai H, Chongsuvivatwong V, Naimpasan O, 
Akarasewi P. Integrated counseling and screening for tuberculosis 
and HIV among household contacts of tuberculosis patients in an 
endemic area of HIV infection: Chiang Rai, Thailand. 
Int J Tuberc Lung Dis 2003; 7 (suppl 3): S424–31.
88 Becerra MC, Pachao-Torreblanca IF, Bayona J, et al. Expanding 
tuberculosis case detection by screening household contacts. 
Public Health Rep 2005; 120: 271–77.
89 Bayona J, Chavez-Pachas AM, Palacios E, Llaro K, Sapag R, 
Becerra MC. Contact investigations as a means of detection and 
timely treatment of persons with infectious multidrug-resistant 
tuberculosis. Int J Tuberc Lung Dis 2003; 7 (suppl 3): S501–09.
90 Carvalho AC, DeRiemer K, Nunes ZB, et al. Transmission of 
Mycobacterium tuberculosis to contacts of HIV-infected tuberculosis 
patients. Am J Respir Crit Care Med 2001; 164: 2166–71.
91 Teixeira L, Perkins MD, Johnson JL, et al. Infection and disease 
among household contacts of patients with multidrug-resistant 
tuberculosis. Int J Tuberc Lung Dis 2001; 5: 321–28.
92 Demissie M, Zenebere B, Berhane Y, Lindtjorn B. A rapid survey 
to determine the prevalence of smear-positive tuberculosis in 
Addis Ababa. Int J Tuberc Lung Dis 2002; 6: 580–84.
93 Sekandi JN, Neuhauser D, Smyth K, Whalen CC. Active case 
ﬁ nding of undetected tuberculosis among chronic coughers in 
a slum setting in Kampala, Uganda. Int J Tuberc Lung Dis 2009; 
13: 508–13.
94 Guwatudde D, Zalwango S, Kamya MR, et al. Burden of 
tuberculosis in Kampala, Uganda. Bull World Health Organ 2003; 
81: 799–805.
95 Corbett EL, Bandason T, Cheung YB, et al. Undiagnosed infectious 
tuberculosis in Harare, Zimbabwe: HIV, past TB treatment and 
other risk factors. 38th World Conference on Lung Health of the 
International Union Against Tuberculosis and Lung Disease; 
Cape Town, South Africa; Nov 8–12, 2007. Abstract PS-72125-12.
96 Corbett EL, Bandason T, Cheung YB, et al. Epidemiology of 
tuberculosis in a high HIV prevalence population provided with 
enhanced diagnosis of symptomatic disease. PLoS Med 2007; 
4: e22.
97 den Boon S, van Lill SW, Borgdorﬀ  MW, et al. High prevalence of 
tuberculosis in previously treated patients, Cape Town, 
South Africa. Emerg Infect Dis 2007; 13: 1189–94.
102 www.thelancet.com/infection   Vol 10   February 2010
Review
98 den Boon S, White NW, van Lill SW, et al. An evaluation of 
symptom and chest radiographic screening in tuberculosis 
prevalence surveys. Int J Tuberc Lung Dis 2006; 10: 876–82.
99 Pronyk PM, Joshi B, Hargreaves JR, et al. Active case ﬁ nding: 
understanding the burden of tuberculosis in rural South Africa. 
Int J Tuberc Lung Dis 2001; 5: 611–18.
100 Khanani M, Ahmed I, Ansari A. Tuberculosis and HIV infecteion 
among drug users and males having sex with males. 39th World 
Conference on Lung Health of the International Union Against 
Tuberculosis and Lung Disease; Paris, France; Oct 16–20, 2008. 
Abstract PC-82284-18.
101 De Cock KM, Chaisson RE. Will DOTS do it? A reappraisal of 
tuberculosis control in countries with high rates of HIV infection. 
Int J Tuberc Lung Dis 1999; 3: 457–65.
102 Lucas SB, Hounnou A, Peacock C, et al. The mortality and 
pathology of HIV infection in a west African city. AIDS 1993; 
7: 1569–79.
103 Borgdorﬀ  MW, Floyd K, Broekmans JF. Interventions to reduce 
tuberculosis mortality and transmission in low- and middle-income 
countries. Bull World Health Organ 2002; 80: 217–27.
104 Murray CJ, Salomon JA. Modeling the impact of global tuberculosis 
control strategies. Proc Natl Acad Sci USA 1998; 95: 13881–86.
105 Ward HA, Marciniuk DD, Pahwa P, Hoeppner VH. Extent of 
pulmonary tuberculosis in patients diagnosed by active 
compared to passive case ﬁ nding. Int J Tuberc Lung Dis 2004; 
8: 593–97.
106 Verver S, Bwire R, Borgdorﬀ  MW. Screening for pulmonary 
tuberculosis among immigrants: estimated eﬀ ect on severity of 
disease and duration of infectiousness. Int J Tuberc Lung Dis 2001; 
5: 419–25.
107 Harries AD, Hargreaves NJ, Graham SM, et al. Childhood 
tuberculosis in Malawi: nationwide case-ﬁ nding and treatment 
outcomes. Int J Tuberc Lung Dis 2002; 6: 424–31.
108 Pillay T, Khan M, Moodley J, Adhikari M, Coovadia H. Perinatal 
tuberculosis and HIV-1: considerations for resource–limited 
settings. Lancet Infect Dis 2004; 4: 155–65.
109 Enarson D, Rieder H, Arnadottir T, Trébucq A. Technical guide: 
sputum examination for tuberculosis by direct microscopy in low 
income countries. Paris: International Union Against Tuberculosis 
and Lung Diseases, 2000. http://www.theunion.org/index.
php?option=com_guide&task=OpenDownload&id_
download=59&id_guide=32&what=Guide%20Complet%20En 
(accessed Dec 17, 2009).
110 Rieder H, Van Deun A, Kam KM, et al. Priorities for tuberculosis 
bacteriology services in low income countries. Paris: International 
Union Against Tuberculosis and Lung Disease, 2007. http://www.
theunion.org/index.php?option=com_guide&task=OpenDownload
&id_download=107&id_guide=59&what=Guide%20Complet%20En 
(accessed Dec 17, 2009).
111 Krivinka R, Drapela J, Kubik A, et al. Epidemiological and clinical 
study of tuberculosis in the district of Kolin, Czechoslovakia: second 
report (1965–1972). Bull World Health Organ 1974; 51: 59–69.
112 den Boon S, Verver S, Lombard CJ, et al. Comparison of symptoms 
and treatment outcomes between actively and passively detected 
tuberculosis cases: the additional value of active case ﬁ nding. 
Epidemiol Infect 2008; 136: 1342–49.
113 Demissie M, Lindtjorn B, Berhane Y. Patient and health service 
delay in the diagnosis of pulmonary tuberculosis in Ethiopia. 
BMC Public Health 2002; 2: 23.
114 Santha T, Renu G, Frieden TR, et al. Are community surveys to 
detect tuberculosis in high prevalence areas useful? Results of 
a comparative study from Tiruvallur District, South India. 
Int J Tuberc Lung Dis 2003; 7: 258–65.
115 Cassels A, Heineman E, LeClerq S, Gurung PK, Rahut CB. 
Tuberculosis case-ﬁ nding in Eastern Nepal. Tubercle 1982; 
63: 175–85.
116 Murray CJ, Salomon JA. Expanding the WHO tuberculosis control 
strategy: rethinking the role of active case-ﬁ nding. 
Int J Tuberc Lung Dis 1998; 2 (suppl 1): S9–15.
117 Hausler HP, Sinanovic E, Kumaranayake L, et al. Costs of measures 
to control tuberculosis/HIV in public primary care facilities in 
Cape Town, South Africa. Bull World Health Organ 2006; 84: 528–36.
